Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 13/20 | 0.61 |
| ▸ | F2 | P00734 | 7/20 | 0.61 |
| ▸ | GPR139 | Q6DWJ6 | 3/20 | 0.50 |
| ▸ | PRKACA | P17612 | 2/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.49 |
| ▸ | GSK3B | P49841 | 2/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
| ▸ | GRK5 | P34947 | 1/20 | 0.49 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | PRKX | P51817 | 1/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871836 | 1.00 | F7 (0.61) | F7F2GPR139PRKACAGSK3A | |
| SCHEMBL4956858 | 0.92 | F7 (0.70) | F7F2GPR139PRKACAGSK3A | |
| SCHEMBL4961418 | 0.92 | F7 (0.70) | F7F2GPR139PRKACAGSK3A | |
| SCHEMBL4956873 | 0.92 | F7 (0.70) | F7F2GPR139PRKACAGSK3A | |
| SCHEMBL3862743 | 0.86 | F7 (0.56) | F7F2GPR139F10 | |
| SCHEMBL13936380 | 0.86 | F7 (0.56) | F7F2GPR139F10 | |
| SCHEMBL3871293 | 0.86 | F7 (0.56) | F7F2GPR139F10 | |
| SCHEMBL3863203 | 0.83 | F7 (0.84) | F7F2GPR139F10 | |
| SCHEMBL4958059 | 0.77 | F7 (0.66) | F7F2GPR139F10 | |
| SCHEMBL4958048 | 0.77 | F7 (0.66) | F7F2GPR139F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090041747-A1 | Compounds for Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISK HEALTH CARE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20090041747-A1 | Compounds for Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISK HEALTH CARE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| US-20090041747-A1 | Compounds for Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISK HEALTH CARE AG (CH) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041747-A1 | Compounds for Stabilizing Factor VII Polypeptide Formulations | F7, F5, F13B | F7 1/4885F2 13/4885GPR139 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.